Di seguito troverete le principali pubblicazioni per ogni unità operative. Per visualizzare l'elenco completo consulta l'archivio IRIS

Biologia Strutturale e Cellulare

1. Bruzzone S, Moreschi I, Usai C, Guida L, Damonte G, Salis A, Scarfì S, Millo E, De Flora A, Zocchi E. Abscisic acid is an endogenous cytokine in human granulocytes with cyclic ADP-ribose as second messenger. Proc Natl Acad Sci USA. 2007 Apr 3;104(14):5759-64. Epub 2007 Mar 26. PMID:17389374
2. Scapolla C, Cangemi G, Barco S, Barbagallo L, Bugnone D, Maffia A, Melioli G,Profumo A, Benatti U, Damonte G. Identification and structural characterization by LC-ESI-IONTRAP and LC-ESI-TOF of some metabolic conjugation products of homovanillic acid in urine of neuroblastoma patients. J Mass Spectrom. 2012, Jul;47(7):816-24.PMID: 22791248.
3. De Castro C, Molinaro A, Piacente F, Gurnon JR, Sturiale L, Palmigiano A, Lanzetta R, Parrilli M, Garozzo D, Tonetti MG, Van Etten JL. Structure of N-linked oligosaccharides attached to chlorovirus PBCV-1 major capsid protein reveals unusual class of complex N-glycans. Proc Natl Acad Sci U S A. 2013, 20;110(34):13956- PMID: 23918378
4. Magnone M, Ameri P, Salis A, Andraghetti G, Emionite L, Murialdo G, De Flora A, Zocchi E. Microgram amounts of abscisic acid in fruit extracts improve glucose tolerance and reduce insulinemia in rats and in humans. FASEB J. 2015 Aug 4. pii: fj.15-277731. [Epub ahead of print]. PMID: 26243865

Immunologia Clinica

1. Parodi A., Traverso P., Kalli F., Conteduca G., Tardito S, Curto M, Grillo F, Mastracci L, Bernardi C, Nasi G, Minaglia F, Simonato A, Carmignani G, Ferrera F, Fenoglio D, Filaci G. Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence. - Oncotarget. 2016 Jan 25. doi: 10.18632/oncotarget.7024.
2. Dentone C, Di Biagio A, Parodi A, Bozzano F, Fraccaro P, Signori A, Cenderello G, Mantia E, Orofino G, De Maria A, Filaci G, Fenoglio D. Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients.AIDS. 2014 Apr 24;28(7):1071-4. doi: 10.1097/QAD.0000000000000194.PMID:24499952
3. Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G, Setti M, Sobrero A, Boccardo F, Cittadini G, Puppo F, Criscuolo D, Carmignani G, Indiveri F, Filaci G. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother. 2013 Jun;62(6):1041-52. doi: 10.1007/s00262-013-1415-9. Epub 2013 Apr 17.PMID:23591981
4. Parodi A, Battaglia F, Kalli F, Ferrera F, Conteduca G, Tardito S, Stringara S, Ivaldi F, Negrini S, Borgonovo G, Simonato A, Traverso P, Carmignani G, Fenoglio D, Filaci G. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes. Cancer Immunol Immunother. 2013 May;62(5):851-62. doi: 10.1007/s00262-013-1392-z. Epub 2013 Jan 29.PMID:23359087